Orphan Biosimilars: Developers See Big Prospects In Small Markets; Soliris Is One Target
Executive Summary
Using lessons learned from the first wave of biosimilar approvals – and citing high prices in the US – some developers are starting to 'think small' with biosimilars for rare disease markets. Alexion’s Soliris is a case in point.
You may also be interested in...
Biopharma Stocks June 2017: BIO’s Rallying Cry Gets A Response
In this month’s stock column, after the Nasdaq Biotech Index (NBI) shot up over 10% at end of June, Scrip focuses on the biopharma companies that propelled that surge. It looks as if investors have been influenced by the BIO Convention held in San Diego, the industry’s biggest forum for self-promotion.
The Birth Of An Orphan Biosimilar Market
Hard-won experience from the first wave of broad-market biosimilars will inform development of "orphan biosimilars," but Navigant Consulting says that biopharmas entering this orphan market will face a unique set of challenges.
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.